Cargando…

Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia

SIMPLE SUMMARY: The use of ibrutinib has changed the management and clinical history of patients with multiple-treated chronic lymphocytic leukemia (CLL). Nevertheless, an increasing number of patients develop resistance to treatment, with mechanisms still to be fully clarified. Since HSP70 plays a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frezzato, Federica, Visentin, Andrea, Severin, Filippo, Pizzo, Serena, Ruggeri, Edoardo, Mouawad, Nayla, Martinello, Leonardo, Pagnin, Elisa, Trimarco, Valentina, Tonini, Alessia, Carraro, Samuela, Pravato, Stefano, Imbergamo, Silvia, Manni, Sabrina, Piazza, Francesco, Brunati, Anna Maria, Facco, Monica, Trentin, Livio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582437/ https://www.ncbi.nlm.nih.gov/pubmed/34771616 http://dx.doi.org/10.3390/cancers13215453

Ejemplares similares

Is It Still Possible to Think about HSP70 as a Therapeutic Target in Onco-Hematological Diseases?
por: Mouawad, Nayla, et al.
Publicado: (2023)

Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia
por: Visentin, Andrea, et al.
Publicado: (2020)

In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment
por: Severin, Filippo, et al.
Publicado: (2019)

P054: The Kinase CK2 is deregulated and targetable in classical Hodgkin Lymphoma
por: Visentin, Andrea, et al.
Publicado: (2022)

Abnormal regulation of BCR signalling by c-Cbl in chronic lymphocytic leukaemia
por: Martini, Veronica, et al.
Publicado: (2018)

HS1, a Lyn Kinase Substrate, Is Abnormally Expressed in B-Chronic Lymphocytic Leukemia and Correlates with Response to Fludarabine-Based Regimen
por: Frezzato, Federica, et al.
Publicado: (2012)

Protein Phosphorylation and Redox Status: An as Yet Elusive Dyad in Chronic Lymphocytic Leukemia
por: Pagano, Mario Angelo, et al.
Publicado: (2022)

Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells
por: Tibaldi, Elena, et al.
Publicado: (2017)

Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases
por: Visentin, Andrea, et al.
Publicado: (2017)

Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival
por: Trimarco, Valentina, et al.
Publicado: (2015)

The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia
por: Visentin, Andrea, et al.
Publicado: (2019)

The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy
por: Castellani, Francesca, et al.
Publicado: (2020)

A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency
por: Visentin, Andrea, et al.
Publicado: (2022)

The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation
por: Visentin, Andrea, et al.
Publicado: (2021)

RhoA Activation Sensitizes Cells to Proteotoxic Stimuli by Abrogating the HSF1-Dependent Heat Shock Response
por: Meijering, Roelien A. M., et al.
Publicado: (2015)

A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells
por: Yigit, Burcu, et al.
Publicado: (2016)

P1076: A RETROSPECTIVE ANALYSIS ON OLD AND EMERGING PROGNOSTIC FACTORS IN CLASSICAL HODGKIN’S LYMPHOMA IN THE PET-GUIDED ERA
por: Cellini, A., et al.
Publicado: (2022)

Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients
por: Barilà, Gregorio, et al.
Publicado: (2021)

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
por: Visentin, Andrea, et al.
Publicado: (2022)

Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation
por: Barilà, Gregorio, et al.
Publicado: (2018)

Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma
por: Manni, Sabrina, et al.
Publicado: (2022)

Glycerophosphoinositol Promotes Apoptosis of Chronic Lymphocytic Leukemia Cells by Enhancing Bax Expression and Activation
por: Boncompagni, Gioia, et al.
Publicado: (2022)

p66Shc Deficiency in Chronic Lymphocytic Leukemia Promotes Chemokine Receptor Expression Through the ROS-Dependent Inhibition of NF-κB
por: Tatangelo, Vanessa, et al.
Publicado: (2022)

HSF1 and HSF3 cooperatively regulate the heat shock response in lizards
por: Takii, Ryosuke, et al.
Publicado: (2017)

From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance
por: Visentin, Andrea, et al.
Publicado: (2022)

Successful treatment of “accelerated” chronic lymphocytic leukemia with single agent ibrutinib: A report of two cases.
por: Xie, John, et al.
Publicado: (2021)

Genome-Wide Characterization and Expression of the Hsf Gene Family in Salvia miltiorrhiza (Danshen) and the Potential Thermotolerance of SmHsf1 and SmHsf7 in Yeast
por: Qu, Renjun, et al.
Publicado: (2023)

The isopeptidase inhibitor 2cPE triggers proteotoxic stress and ATM activation in chronic lymphocytic leukemia cells
por: Tomasella, Andrea, et al.
Publicado: (2016)

Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
por: Mauro, Francesca Romana, et al.
Publicado: (2021)

HSF2 cooperates with HSF1 to drive a transcriptional program critical for the malignant state
por: Smith, Roger S., et al.
Publicado: (2022)

Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience
por: Calabretto, Giulia, et al.
Publicado: (2022)

Ibrutinib-induced cardiomyopathy
por: Kyi, Htay Htay, et al.
Publicado: (2019)

Extrahepatic metabolism of ibrutinib
por: Rood, Johannes J. M., et al.
Publicado: (2020)

Comment on: “Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients”
por: Visentin, Andrea, et al.
Publicado: (2021)

Almond Skin Extracts Abrogate HSV-1 Replication by Blocking Virus Binding to the Cell
por: Bisignano, Carlo, et al.
Publicado: (2017)

Quantitative Comparison of HSF1 Activators
por: Steurer, Christoph, et al.
Publicado: (2022)

Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort
por: Reda, Gianluigi, et al.
Publicado: (2022)

HSF1Base: A Comprehensive Database of HSF1 (Heat Shock Factor 1) Target Genes
por: Kovács, Dániel, et al.
Publicado: (2019)

Genome-Wide Identification of Petunia HSF Genes and Potential Function of PhHSF19 in Benzenoid/Phenylpropanoid Biosynthesis
por: Fu, Jianxin, et al.
Publicado: (2022)

Ibrutinib: Rebound effect in the form of respiratory deterioration following the discontinuation of ibrutinib: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rbthjceuabjv6frd3315j1ctvv